Last reviewed · How we verify

NCT06703723: SEM-COV-19

Impact of Cryopreservation Methods on Post-Thaw SARS-CoV-2 in Semen Samples

Completed Last updated 25 November 2024
What this trial tests

trial in COVID 19 in 40 participants. Completed in 16 April 2021.

Timeline
14 January 2021
Primary endpoint
16 April 2021
16 April 2021

Quick facts

Lead sponsorIstituto Clinico Humanitas
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date14 January 2021
Primary completion16 April 2021
Estimated completion16 April 2021
Sites1 location across Italy

Conditions studied

Sponsor

Istituto Clinico Humanitas

Who can join

Adults 18 to 50, male only, with COVID 19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cryopreservation of seminal fluid or spermatozoa from epididymary and testicular retrieval represents a crucial tool in managing conditions of permanent or temporary infertility, as well as in cases of secretory and excretory azoospermia. These pathologies often affect young men and children, making it essential to maintain fertility through cryopreservation methods such as vitrification or two-step cryopreservation of human semen. The burden of the SARS-CoV-2 virus has rapidly evolved. SARS-CoV-2 causes respiratory, cardiovascular, digestive, and urinary infections, yet no studies have explored its effects on the reproductive system. Recent findings confirm the expression of the virus receptor (ACE2) on certain testicular cells, including Sertoli cells, Leydig cells, and spermatogonia, which could significantly impact fertility and cryopreservation practices. This study aims to utilize semen samples from individuals exposed to SARS-CoV-2 infection to perform two different cryopreservation procedures, evaluating virus behavior and effects. The objective is to determine whether it is safer to cryopreserve the entire volume of the sample or perform gradient separation to isolate the virus from spermatozoa, potentially establishing a new cryopreservation protocol specific to SARS-CoV-2.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID 19

Currently open trials in the same condition.

Other Istituto Clinico Humanitas trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06703723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing